Cargando…

Ikaros as a downstream mediator of BCR blockade therapy in B-cell non-Hodgkin lymphoma

Detalles Bibliográficos
Autores principales:	Ribeiro, Marcelo Lima, Normant, Emmanuel, Roué, Gaël
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9708099/ https://www.ncbi.nlm.nih.gov/pubmed/36458104 http://dx.doi.org/10.18632/oncoscience.568

Ejemplares similares

Antitumor Activity of the Novel BTK Inhibitor TG-1701 Is Associated with Disruption of Ikaros Signaling in Patients with B-cell Non–Hodgkin Lymphoma
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2021)

Recent Advances in the Targeting of Epigenetic Regulators in B-Cell Non-Hodgkin Lymphoma
por: Ribeiro, Marcelo L., et al.
Publicado: (2019)

G protein-coupled receptor 183 mediates the sensitization of Burkitt lymphoma tumors to CD47 immune checkpoint blockade by anti-CD20/PI3Kδi dual therapy
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2023)

Epigenetic targets in B- and T-cell lymphomas: latest developments
por: Ribeiro, Marcelo Lima, et al.
Publicado: (2023)

Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma
por: Balsas, P., et al.
Publicado: (2017)

Editorial: The molecular landscape and promising therapeutic targets in aggressive B-cell non-Hodgkin lymphomas
por: Witte, Hanno Maximilian, et al.
Publicado: (2023)

The BET bromodomain inhibitor CPI203 improves lenalidomide and dexamethasone activity in in vitro and in vivo models of multiple myeloma by blockade of Ikaros and MYC signaling
por: Díaz, Tania, et al.
Publicado: (2017)

Immune-Checkpoint Inhibitors in B-Cell Lymphoma
por: Armengol, Marc, et al.
Publicado: (2021)

Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas
por: Profitós-Pelejà, Núria, et al.
Publicado: (2022)

Genetic analysis of Ikaros target genes and tumor suppressor function in BCR-ABL1(+) pre–B ALL
por: Schjerven, Hilde, et al.
Publicado: (2017)

The riddle of lymphoma BCR-antigenes
por: Thurner, Lorenz, et al.
Publicado: (2018)

BFL-1 expression determines the efficacy of venetoclax in MYC+/BCL2+ double hit lymphoma
por: Esteve-Arenys, Anna, et al.
Publicado: (2018)

Antitumor Activity of Simvastatin in Preclinical Models of Mantle Cell Lymphoma
por: Santos, Juliana Carvalho, et al.
Publicado: (2022)

The real risk of secondary non-Hodgkin lymphoma following classical Hodgkin lymphoma
por: Dogan, Ahmet
Publicado: (2022)

Immunotherapies in Non-Hodgkin’s Lymphoma
por: Bezombes, Christine, et al.
Publicado: (2021)

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma
por: Krönke, Jan, et al.
Publicado: (2017)

Targeting of heme oxygenase-1 attenuates the negative impact of Ikaros isoform 6 in adult BCR-ABL1-positive B-ALL
por: Lin, Xiaojing, et al.
Publicado: (2016)

Ikaros deficiency is associated with aggressive BCR-ABL1 B-cell precursor acute lymphoblastic leukemia independent of the lineage and developmental origin
por: Simand, Célestine, et al.
Publicado: (2021)

Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma
por: Lin, Adam Yuh, et al.
Publicado: (2022)

Pharmacological Targeting of BET Bromodomain Proteins in Acute Myeloid Leukemia and Malignant Lymphomas: From Molecular Characterization to Clinical Applications
por: Reyes-Garau, Diana, et al.
Publicado: (2019)

Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation
por: Dlouhy, Ivan, et al.
Publicado: (2021)

Interleukin-1 receptor associated kinase 1/4 and bromodomain and extra-terminal inhibitions converge on NF-κB blockade and display synergistic antitumoral activity in activated B-cell subset of diffuse large B-cell lymphoma with MYD88 L265P mutation
por: Dlouhy, Ivan, et al.
Publicado: (2022)

The bioengineered HALOA complex induces anoikis in chronic myeloid leukemia cells by targeting the BCR-ABL/Notch/Ikaros/Redox/Inflammation axis
por: Singh, Vivek, et al.
Publicado: (2022)

Systems-wide analysis of BCR signalosomes and downstream phosphorylation and ubiquitylation
por: Satpathy, Shankha, et al.
Publicado: (2015)

PD-1 blockade enhances cytokine-induced killer cell-mediated cytotoxicity in B-cell non-Hodgkin lymphoma cell lines
por: Li, Yutao, et al.
Publicado: (2021)

Management of Drug Resistance in Mantle Cell Lymphoma
por: Roué, Gaël, et al.
Publicado: (2020)

Clinical Management of Long-Term Survivors after Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma
por: Bari, Alessia, et al.
Publicado: (2022)

Second cancer risk following Hodgkin lymphoma
por: Sud, Amit, et al.
Publicado: (2017)

The Ikaros family of zinc-finger proteins
por: Fan, Yingzhi, et al.
Publicado: (2016)

Gads (Grb2-related adaptor downstream of Shc) is required for BCR-ABL-mediated lymphoid leukemia
por: Gillis, LC, et al.
Publicado: (2013)

Managing advanced stage Hodgkin lymphoma
por: Saikia, TK
Publicado: (2015)

Ikaros antagonizes DNA binding by STAT5 in pre-B cells
por: Heizmann, Beate, et al.
Publicado: (2020)

Expression of PAX-5 in B Cell Hodgkin and Non Hodgkin Lymphoma
por: Khan, Muhammad Rahil, et al.
Publicado: (2018)

Bringing circulating tumor DNA to the clinic in Hodgkin lymphoma
por: Kurtz, David M.
Publicado: (2021)

Regulatory Phosphorylation of Ikaros by Bruton's Tyrosine Kinase
por: Ma, Hong, et al.
Publicado: (2013)

Sumoylation Inhibits the Growth Suppressive Properties of Ikaros
por: Apostolov, Apostol, et al.
Publicado: (2016)

Radioimmunotherapy of B-Cell Non-Hodgkin’s Lymphoma
por: Bodet-Milin, Caroline, et al.
Publicado: (2013)

Ikaros mediates gene silencing in T cells through Polycomb repressive complex 2
por: Oravecz, Attila, et al.
Publicado: (2015)

Non-Hodgkin lymphoma mimicking cholangiocarcinoma
por: Mendes, Gustavo Gomes, et al.
Publicado: (2019)

Progress in understanding the biology of nodular lymphocyte-predominant Hodgkin lymphoma
por: Straus, David J.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_m9dqdnnv6pj02aadjpv1dtg4i2